Sanofi: Positive results of sarilumab in efficacy, question on the safety

BUY, Fair Value EUR84.5 (+8%)

News published on November Friday 22, 2013
Share on

Sanofi is delivering positive phase III results in efficacy for sarilumab, an anti-IL6 receptor fully-human antibody, developed together with Regeneron in RA (rheumatoid arthritis). Sarilumab is actually very similar to tocilizumab, a drug marketed by the Roche Group under the brand name Actemra.

Full report available to subscribers
Please contact   

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities